siG12D

siG12D is a small interfering RNA (siRNA) specifically designed to target the KRAS gene bearing the G12D mutation, which is commonly found in pancreatic cancer and other malignancies. By promoting RNA interference, siG12D silences mutant KRAS mRNA, thereby reducing expression of the oncogenic KRAS protein and inhibiting tumor cell growth and proliferation. The drug has been formulated for clinical use as siG12D-LODER, in which the siRNA is encapsulated within a biodegradable polymer matrix (LODER) that enables prolonged local release within the tumor microenvironment following endoscopic implantation. Developed primarily for locally advanced pancreatic cancer, siG12D-LODER is administered in addition to standard chemotherapy and is designed to overcome challenges associated with systemic siRNA delivery, such as rapid degradation and lack of tumor specificity. Preclinical studies and early-phase clinical trials have shown that siG12D-LODER effectively reduces KRAS levels, triggers tumor necrosis, impairs tumor cell migration, and inhibits epithelial-mesenchymal transition. The approach was well tolerated in clinical studies and is under further investigation in multinational, randomized trials for pancreatic cancer[1][2][3][4][5][7].

Brand names

siG12D-LODERsiG-12D-LODERsiG 12D-LODER

Other names

anti-KRASG12D siRNAanti-KRASG-12D siRNAanti-KRASG 12D siRNAsiRNA-G12DsiRNA-G-12DsiRNA-G 12DKRAS-targeting siRNA